The top biopharma conferences in 2027

Clinical trial results are the key events that make or break a biotechnology company. Positive data can validate a drugmaker’s business plan and boost its stock price, while a disappointing readout can change its course. These crucial findings are often presented and closely analyzed at medical conferences throughout the year — meetings where companies get to showcase the medicines they’ve staked their futures on.

These conferences have different focuses. Some spotlight early research or the final trials that can yield regulatory approvals. Others are temperature takers for the industry’s health, where companies and investors gather to network and cut deals.

Below, BioPharma Dive has collected schedules for the key medical meetings and conferences planned for 2027.

Top medical and industry meetings in 2027

J.P. Morgan Healthcare Conference

Jan. 11-14
San Francisco

Every year, biopharma investors and executives descend on San Francisco’s Union Square to talk deals. With luck, a handful of companies will have new acquisitions or partnerships to announce during the meeting’s first few days — M&A activity that could be a harbinger of what's to come in the year ahead.

BIO Investment & Growth Summit

Feb. 16-17
Miami

A meeting once called the CEO and Investor Conference and hosted in New York will be held in Miami Beach under a newer name in 2027. Still, the gathering will have an investor focus, with networking opportunities for biotechnology CEOs and their backers.

MDA Clinical & Scientific Conference

March 21-24
Orlando, Florida

Hosted by the Muscular Dystrophy Association, a prominent patient advocacy group, the meeting showcases promising research in neuromuscular disease and brings together industry leaders, physicians and scientists to discuss important clinical trial results and real-world data.

American Association for Cancer Research Annual Meeting

April 2-7
Orlando, Florida

While the American Society of Clinical Oncology’s meeting often gets billed as the field’s largest conference, AACR has become an equally major gathering for cancer science, particularly earlier-stage findings on new drug mechanisms of action or treatment modalities.

American College of Cardiology Annual Scientific Session

April 10-12
Houston

The growing body of evidence showing that GLP-1 medicines can affect a variety of cardiometabolic conditions, and the sheer number of clinical trials underway in obesity, makes ACC a meeting likely to feature presentations that inform the field’s direction.

American Academy of Neurology Annual Meeting

May 1-5
Washington, D.C.

AAN often features the latest findings in research for diseases like Alzheimer’s and Parkinson’s, making it one of the top forums for assessing recent progress in neuroscience.

American Society of Gene and Cell Therapy Annual Meeting

May 3-7
Philadelphia

ASGCT has grown with the cell and gene therapy field, becoming a premier conference as the sector expanded and treatments advanced further into human testing. While such therapies still offer much promise, the difficulties companies face successfully marketing them have made the meeting a health check for the sector as well.

American Society of Clinical Oncology Annual Meeting

June 4-8
Chicago

ASCO is a lodestone for cancer drug research with the highest profile and widest impact. The data presented each year at McCormick Place in Chicago often changes treatment standards, as well as makes (or breaks) the fortunes of drug developers.

BIO International Convention

June 7-10
Philadelphia

BIO’s International Convention is always an important convener for biotech and pharma companies’ business development teams. It’s also regularly a venue for industry leaders to discuss and debate the top challenges facing the sector.

European Hematology Association Congress

June 10-13
Barcelona, Spain

EHA is one of the year’s biggest meetings devoted specifically to hematology and includes results at the forefront of research into leukemias, lymphomas and non-malignant blood diseases like sickle cell disease.

European Association for the Study of the Liver Congress

June 16-19
London

From hepatitis C to MASH, the burden of liver diseases is large and costly. Europe’s main hepatology meeting is an international forum for the latest research into these disorders as clinicians present data on risk factors and new treatment approaches.

American Diabetes Association’s Scientific Sessions

June 18-21
Washington, D.C.

ADA is one of the largest medical meetings focused on diabetes and frequently features new research on the care and treatment of differing patient populations with the condition.

European Society of Cardiology Annual Congress

Aug. 27-30
Milan

ESC brings together tens of thousands of cardiology experts to discuss practice-changing research in heart disease. The meeting has been a recent venue for important study results from Alnylam Pharmaceuticals, Novo Nordisk and AstraZeneca, among other companies.

World Conference on Lung Cancer

Sept. 11-14
Denver

WCLC is the world’s top conference on advances in lung cancer, one of the most competitive areas in oncology and a coveted market among drugmakers. Over the last couple years, the WCLC has been the forum for advances among a closely watched group of cancer immunotherapies called PD-1/VEGF inhibitors, which could change the way many lung tumors are treated.

European Society for Medical Oncology Congress

Sept. 17-21
Barcelona, Spain

ESMO is Europe’s answer to the American Society of Clinical Oncology’s annual meeting and just as often features standard-shifting cancer research. While immunotherapy remains an active area of exploration for drugmakers, increasingly other treatment types like antibody-drug conjugates and radiopharmaceuticals have been featured at oncology conferences.

European Association for the Study of Diabetes

Sept. 20-24
Budapest, Hungary

The EASD meeting is another important showcase for the “incretin” diabetes and weight loss medicines that have soared in popularity in recent years. The 2026 edition spotlighted a wave of next-generation obesity therapies, among them a treatment that could help Eli Lilly extend its market-leading franchise.